This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Surmodics' (SRDX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) sees solid segmental performance in fiscal Q4; gains from alliance with Abbott.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $72.96, marking a +0.63% move from the previous day.
Abbott (ABT) Q3 Earnings Top Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 1.35% and -0.12%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $69.30, moving +1.91% from the previous trading session.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $67.68 in the latest trading session, marking a +1.11% move from the prior day.
DexCom Launches CLARITY Mobile App, Strengthens CGM Profile
by Zacks Equity Research
DexCom (DXCM) benefits from the diabetes care space as it adopts cloud-based services for Continuous Glucose Monitoring.
Abbott (ABT) Q3 Earnings Top Estimates, Guidance Narrowed
by Zacks Equity Research
Within Structural Heart, growth was driven by several product areas across Abbott's (ABT) broad portfolio, including AMPLATZER PFO Occluder and MitraClip.
Bank Stocks Earnings Scorecard, Fed Minutes, & Trade Talks on "Hiatus"
by Ryan McQueeney
Ryan McQueeney discusses the upcoming Fed minutes and Wilbur Ross' comments about U.S.-China trade talks. He also recaps earnings reports from United, Abbot Labs, and U.S. Bancorp. Later, he takes at a look at the earnings scorecard for bank stocks.
Earnings & Economic Data Deluge
by Zacks Equity Research
Earnings & Economic Data Deluge
Q3 Earnings Stay (Mostly) Strong, Plus Housing Data
by Mark Vickery
With new Housing Starts, Building Permits and Mortgage Application data, we continue to collect new Q3 earnings results, particularly from UAL, ABT and USB.
Abbott (ABT) Q3 Earnings Top Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 1.35% and -0.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Earnings Charts in the Spotlight
by Tracey Ryniec
Want to know what's going on in the global economy? Check in with these five companies reporting earnings this week.
Can Abbott's (ABT) Steady Overall Growth Aid Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) is consistently well-placed on a healthy growth trajectory within its Diabetes Care business for the past few quarters.
Why Abbott Laboratories (ABT) Might Surprise This Earnings Season
by Zacks Equity Research
Abbott Laboratories (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $69.33, moving +1.39% from the previous trading session.
Abbott (ABT) Q3 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Stock Reports for Apple, Microsoft & Pfizer
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Microsoft (MSFT) and Pfizer (PFE).
Will Walgreens (WBA) Q4 Earnings Gain From Overall Strength?
by Zacks Equity Research
Several planned developments, early benefits of new pharmacy contracts as well as an increase in volume are consistently driving growth within Walgreens Boots' (WBA) Retail Pharmacy USA division.
US Diabetes Market Gaining Momentum: 3 Stocks in Focus
by Sreyoshi Mukherjee
A rising geriatric population and lifestyle disorders are expanding the U.S. diabetic population.
Abbott's CE Mark for FreeStyle Libre 2 Boosts Diabetes Arm
by Zacks Equity Research
Abbott (ABT) focuses on boosting diabetes care. The latest CE Mark will increase the top-line contributions from the Diabetes unit.
Abbott's Troponin-I Wins CE Mark, Vascular Arm Gets a Revamp
by Zacks Equity Research
Abbott's (ABT) life-changing High Sensitive Troponin-I test uses a biomarker, specific to the heart.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech
Why Abbott (ABT) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abbott Banks on New Approvals and Buyouts, Competition Rife
by Zacks Equity Research
Abbott's (ABT) receipt of FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement approval in Japan for the same device will help it revive the dull Vascular business.
ABT or PETQ: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ABT vs. PETQ: Which Stock Is the Better Value Option?